https://sputnikglobe.com/20240603/drug-melts-away-bowel-cancer-say-uk-doctors-1118750612.html
Drug ‘Melts Away’ Bowel Cancer, Say UK Doctors
Drug ‘Melts Away’ Bowel Cancer, Say UK Doctors
Sputnik International
A new study suggests an already in use cancer drug could greatly improve outcomes for some patients with bowel cancer, eliminating the need for chemotherapy and even surgery in many cases.
2024-06-03T01:48+0000
2024-06-03T01:48+0000
2024-06-03T01:48+0000
beyond politics
american society of clinical oncology
keytruda
cancer
cancer treatment
science & tech
https://cdn1.img.sputnikglobe.com/img/07e6/08/0b/1099491234_0:64:1229:755_1920x0_80_0_0_db7cab10f9886605442f9a8adebec6f5.jpg
The study followed 32 patients with stage two or three bowel cancer who were MMR deficient /MSI-High bowel cancer (aka mismatch repair cancer syndrome) which means they have a high level of deficient cells with a large number of genetic mutations.The patients were given nine weeks of pembrolizumab, also known as Keytruda, instead of chemotherapy ahead of their surgery. At the end of the nine weeks, 59% of the patients had no cancer remaining in their body and the other 41% had their remaining cancer successfully removed.Typically, in bowel cancer patients with MMR deficient/MSI-High bowel cancer, less than 5% of patients show no signs of cancer after surgery.Pembrolizumab blocks a specific protein on the surface of cells, compelling them to seek out and destroy cancer cells. The patients also did not have to suffer through post-op chemotherapy, which can be extremely taxing on patients’ bodies.The study was led by the University of College London, University College London Hospital, the Christie National Health Service Foundation Trust in Manchester, St. James’ University Hospital in Leeds, University Hospital Southampton and the University of Glasgow.Pembrolizumab is already used to treat a variety of different cancers, including lung, head, neck, stomach and cervical cancer, along with certain types of breast cancer, Hodgkin's lymphoma and melanoma.The trial will continue over the next few years and will assess the patients’ relapse and overall survival rates.The study was presented at the world’s largest cancer conference the American Society of Clinical Oncology
https://sputnikglobe.com/20240321/russian-doctors-remove-170-lung-cancer-tumors-breaking-world-record-1117464368.html
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
2024
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
keytruda, pembrolizumab, bowel cancer, cancer cures, immunotherapy for cancer, alternatives to chemotherapy
keytruda, pembrolizumab, bowel cancer, cancer cures, immunotherapy for cancer, alternatives to chemotherapy
Drug ‘Melts Away’ Bowel Cancer, Say UK Doctors
Bowel cancer patients with a certain genetic anomaly could have drastically more success defeating it using a drug that doctors say “melts away” tumors, often eliminating the need for surgery and chemotherapy.
The study followed 32 patients with stage two or three bowel cancer who were MMR deficient /MSI-High bowel cancer (aka mismatch repair cancer syndrome) which means they have a high level of deficient cells with a large number of genetic mutations.
The patients were given nine weeks of pembrolizumab, also known as Keytruda, instead of chemotherapy ahead of their surgery. At the end of the nine weeks, 59% of the patients had no cancer remaining in their body and the other 41% had their remaining cancer successfully removed.
Typically, in bowel cancer patients with MMR deficient/MSI-High bowel cancer, less than 5% of patients show no signs of cancer after surgery.
Pembrolizumab blocks a specific protein on the surface of cells, compelling them to seek out and destroy cancer cells. The patients also did not have to suffer through post-op chemotherapy, which can be extremely taxing on patients’ bodies.
The study was led by the University of College London, University College London Hospital, the Christie National Health Service Foundation Trust in Manchester, St. James’ University Hospital in Leeds, University Hospital Southampton and the University of Glasgow.
“Immunotherapy [like pembrolizumab] can make tumors disappear before surgery. If you melt the cancer away before surgery you normally triple survival chances,” Dr. Kai-Keen Shiu, the trial’s chief investigator and a consultant medical oncologist at University College London Hospital, explained. “If patients have a complete response to pembrolizumab it can triple your chance of survival.”
Pembrolizumab is already used to treat a variety of different cancers, including lung, head, neck, stomach and cervical cancer, along with certain types of breast cancer, Hodgkin's lymphoma and melanoma.
Roughly 15% of bowel cancer patients have the genetic makeup that suggests pembrolizumab will be effective for them. Bowel cancer is the second most deadly type of cancer, killing around 900,000 people a year.
The trial will continue over the next few years and will assess the patients’ relapse and overall survival rates.
The
study was presented at the world’s largest cancer conference the American Society of Clinical Oncology
